News & Media | Iambic Therapeutics

NEWS & MEDIA

Read our recent announcements

Press

June 22, 2026

Bayer and Iambic collaborate to advance drug discovery with AI

Presentation

August 1, 2025

Presentation and poster shared at the Gordon Research Conference: High Throughput Chemistry and Chemical Biology

Presentation

July 29, 2025

Video: Iambic Therapeutics CEO Tom Miller on NYSE Floor Talk

Presentation

July 22, 2025

Panel at the Decoding Bio AIxBio Summit at the NYSE

Presentation

July 15, 2025

Presentation at the Gordon Research Conference: Computer Aided Drug Design

Press

July 9, 2025

Revolution Medicines and Iambic Announce Technology and Research Collaboration Using Iambic’s AI Discovery Tools to Pursue New Drug Candidates

Press

June 26, 2025

Iambic takes the lead for Next-Gen AI Drug Discovery with Lambda

Press

June 10, 2025

Iambic Named to CNBC’s 2025 Disruptor 50 List

Press

June 4, 2025

Iambic Completes Dose Escalation in Ongoing Phase 1/1B Study of Lead Program IAM1363, a Small Molecule Inhibitor of Wild-Type and Oncogenic HER2 Mutant Proteins

Press

May 28, 2025

Iambic to Participate in June Investor Conferences

Press

June 22, 2026

Bayer and Iambic collaborate to advance drug discovery with AI

Press

May 19, 2026

Iambic Named to CNBC Disruptor 50 for Second Consecutive Year

Press

May 11, 2026

Iambic to participate in upcoming investor conferences

Press

April 2, 2026

Iambic to Participate in April Investor Conferences

Press

March 2, 2026

Iambic to Participate in March Investor Conferences

Press

February 9, 2026

Iambic Announces Collaboration with Takeda to Advance AI-Driven Design of Small Molecules

Publication

December 7, 2025

Scaling Multi-Modal and Multi-Task Transformers for Small Molecule Drug Discovery

Publication

December 3, 2025

San Diego NeuralPLexer3: Accurate Biomolecular Complex Structure Prediction with Flow Models

Publication

October 19, 2025

A Phase 1/1b Study of IAM1363, a selective and brain penetrant HER2 inhibitor in participants (pts) with advanced cancers harboring HER2 alterations

Publication

September 9, 2025

IAM1363 is a Potent, Selective, and Irreversible HER2 and Pan-HER2 Mutant Small Molecule Inhibitor for the Treatment of HER2-Driven NSCLC

Publication

May 5, 2025

Enchant v2: Pushing the Boundaries of Predictive Drug Discovery

Publication

April 29, 2025

A Novel KIF18A Inhibitor for Targeting Chromosomal Instability in Cancer (AACR 2025 Poster)

Publication

December 16, 2024

NeuralPLexer3: Accurate Biomolecular Complex Structure Prediction with Flow Models

Publication

October 29, 2024

Enchant whitepaper: Breaking the data wall between lab and clinic

Publication

July 24, 2024

Multi-Modal and Multi-Task Transformer for Small Molecule Drug Discovery

Presentation

April 4, 2025

Presentation at Bio IT World Annual Conference

Presentation

April 2, 2025

Panel and fireside chat at the HC Wainwright AI-Based Drug Discovery and Development Conference

Presentation

March 18, 2025

Presentation at the KeyBanc Capital Markets Healthcare Forum

Presentation

March 12, 2025

Presentation at the Pharmaceutical and Bioscience Society

Presentation

March 11, 2025

Presentation at the AI in Drug Discovery Conference

Presentation

March 6, 2025

Fireside chat at the Morgan Stanley Technology, Media and Telecom Conference

Presentation

February 2, 2025

Panel presentation at the Biocom California Annual Partnering and Investor Conference

Presentation

January 14, 2025

Presentation at the 43rd Annual JP Morgan Healthcare Conference

Presentation

January 8, 2025

Podcast: Revolutionizing Drug Discovery with AI

Let's work together

Leverage the Iambic discovery process for your program. Reach out to us at partnerships@iambic.ai.

Contact us